Click Therapeutics develops FDA‑cleared, prescription‑only digital therapeutics delivered via mobile apps that can be used alone or combined with drugs as Software‑Enhanced Drugs™. Leveraging neuroscience, AI‑driven personalization, and digital biomarkers, its platform modulates neurocircuitry to improve efficacy, adherence, and outcomes for neurological, psychiatric, and chronic conditions. The solution integrates with electronic health records, providing clinicians with evidence‑based reports while offering patients engaging, clinically validated interventions on their smartphones.
Funding
$48.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DSFounders
Product
Problem
Patients with many neurological, psychiatric, and chronic diseases often experience gaps in treatment efficacy, adherence, or side‑effect management, and traditional drug therapies alone may not fully address these unmet clinical needs.
Solution
Click Therapeutics creates prescription‑grade digital therapeutics that deliver software‑based interventions via mobile applications. These interventions are regulated as medical devices, undergo clinical validation, and can be prescribed by healthcare providers either as standalone treatments (Prescription Digital Therapeutics) or combined with specific drugs (Software‑Enhanced Drugs™). The platform leverages neuroscience, AI‑driven personalization, and digital biomarkers to modulate neurocircuitry and behavior, thereby augmenting drug efficacy, supporting adherence, and improving patient outcomes. Clinicians receive evidence‑based reports and can integrate the therapy into standard care pathways, while patients access engaging, evidence‑based exercises on their smartphones. The approach is designed to be scalable across multiple indications, including depression, migraine, schizophrenia, opioid use disorder, and oncology, providing a new modality of medicine that bridges pharmacology and software.
Target Audience
Primary customers are pharmaceutical companies seeking to augment their drug portfolios and healthcare providers prescribing digital therapeutics for patients with unmet neurological or behavioral health needs.
Features
- Mobile‑app delivery of FDA‑cleared, prescription‑only software interventions
- AI‑powered personalization and digital biomarker analytics to tailor therapeutic content
- Clinical trial‑backed efficacy claims for both standalone digital therapeutics and drug‑software combination products
- Secure, ISO‑certified software‑as‑medical‑device development lifecycle ensuring regulatory compliance
- Integration capabilities for electronic health records and provider dashboards for outcome monitoring
- QR‑code enabled linking of drug packaging to the companion software in Software‑Enhanced Drug™ offerings